Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330104 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL329927 | 0.91 | DHODH (0.54) | SMN1; SMN2KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL3475608 | 0.84 | TMPRSS4 (0.52) | SMN1; SMN2TMPRSS4MAPT | |
| SCHEMBL330267 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL329799 | 0.82 | MEN1 (0.64) | SMN1; SMN2KDM4EALDH1A1HPGDDHODH | |
| SCHEMBL330403 | 0.81 | TMPRSS4 (0.55) | SMN1; SMN2HPGDTMPRSS4MAPT | |
| SCHEMBL7229694 | 0.77 | ALDH1A1 (0.55) | SMN1; SMN2KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL332059 | 0.76 | TMPRSS4 (0.49) | NPC1RAB9ATMPRSS4RXFP1 | |
| SCHEMBL23742064 | 0.75 | SMN1; SMN2 (0.59) | SMN1; SMN2KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL330478 | 0.75 | TMPRSS4 (0.43) | SMN1; SMN2KDM4EALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503425-B2 | Methods of treating or controlling cytotoxic cerebral edema | AEROMICS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20240360077-A1 | METHODS | AEROMICS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AEROMICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20220081391-A1 | METHODS | AEROMICS, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503425-B2 | Methods of treating or controlling cytotoxic cerebral edema | AQP4, AQP1, AQP3 | SMN1; SMN2 1483/4885KDM4E 1649/4885ALDH1A1 4070/4885 |
| US-20220081391-A1 | METHODS | AQP4, AQP1, AQP3 | SMN1; SMN2 1665/4885KDM4E 1657/4885ALDH1A1 3934/4885 |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AQP4, AQP1, AQP3 | SMN1; SMN2 1164/4885KDM4E 2233/4885ALDH1A1 4133/4885 |
| US-20240360077-A1 | METHODS | AQP4, AQP1, AQP3 | SMN1; SMN2 1618/4885KDM4E 1787/4885ALDH1A1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.